Norris Medicines Ltd (NORRIS) — shareholding pattern, promoter holding, financials and share price
About Norris Medicines Ltd (NORRIS)
Norris Medicines Ltd operates in the Trading & Distributors industry, within the Services sector. It trades on the NSE as NORRIS and on the BSE under scrip code 524414. Its ISIN is INE744C01029.
Incorporated in 1990, Norris Medicines Ltd is a manufacturer of Injections and Medicinal formulations [1]
Norris Medicines Limited is a key player in the healthcare industry, primarily focusing on the manufacturing of injections and medicinal formulations. The company operates two WHO GMP-approved plants in Ankleshwar, Gujarat.
Significant milestones in its portfolio include the introduction of diabetic and cardiac products in 2006, a dental range in 2007, and an enhanced anti-malarial range by 2013. This highlights its expanding and diverse product line over the years.
Listed peers in Trading & Distributors: Onesource Industries & Ventures Ltd, Regent Enterprises Ltd, Hemang Resources Ltd, Neelkanth Ltd, Velox Shipping and Logistics Ltd, Yash Management & Satelite Ltd.
Valuation & Returns
10 Jul 2026At ₹17.87 a share on 10 Jul 2026, Norris Medicines Ltd (NORRIS) was valued at a price-to-earnings ratio of -63.57x against an industry P/E of 21.24x. Solomo computes return on equity of 1.85% and return on capital employed of 3.28% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -63.57x
- Industry P/E
- 21.24x
- EPS (TTM)
- ₹-0.28
- Book value / share
- ₹-14.87
- ROE
- 1.85%
- ROCE
- 3.28%
- ROA
- -2.03%
- Debt / equity
- -1.42x
- Dividend yield
- 0%
- EBITDA margin
- 8.72%
- 52-week range
- ₹12 – ₹19.63
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Norris Medicines Ltd (NORRIS) reported revenue of ₹8.13 crore, net profit of ₹-0.28 crore and earnings per share of ₹-0.28. That compares with revenue of ₹5.82 crore and net profit of ₹-1.24 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1.41 crore and net profit ₹0.05 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 9.44 | 8.36 | 5.64 | 5.82 | 8.13 |
| Net profit (₹ cr) | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 |
| EPS (₹) | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -12.24% | -5.93% | -14.88% | 3.19% |
| Profit growth | - | - | - | -4.20% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 34.01% of Norris Medicines Ltd (NORRIS) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.07%. Market capitalisation was ₹18 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: FAB METALS PRIVATE LIMITED 41.99%, LKP SECURITIES LIMITED 1.5%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 34.01% | - | - | 0.07% | 65.99% |
| Mar 2026 | 34.01% | - | - | 0.07% | 65.99% |
| Dec 2025 | 34% | - | - | 0.07% | 66% |
| Sep 2025 | 34% | - | - | 0.07% | 66% |
| Jun 2025 | 34% | - | - | 0.07% | 66% |
| Mar 2025 | 34% | - | - | 0.07% | 66% |
| Dec 2024 | 34% | - | - | 0.07% | 66% |
| Sep 2024 | 34.01% | - | - | 0.07% | 65.99% |